Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following BL-8040 Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall St set for strongest quarter in years as risk appetite holds despite US-Iran war
- Dollar pushes higher, yen sinks to 40-year low
- Citi says bearish flows are building in Nasdaq and S&P 500
- Patrick and LCI Industries to merge in all-stock deal
- Logitech dips as BofA downgrades stock on demand outlook concerns
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
BioLineRx (BLRX) Bullish Stance Reiterated at Maxim Group After Entering Expansion stage of AML Phase 2 Study
May 4, 2015 11:46 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $8 price target on BioLineRx (NASDAQ: BLRX) after the company announced they have selected the 1.5 mg/kg dose of BL-8040 to move into the expansion phase of the ongoing phase II study in Acute Myeloid Leukemia (AML).
Kolbert highlighted:
With a... MoreBioLineRx (BLRX) Announces Completion of BL-8040 Phase 2 Dose-Escalation Stage
May 4, 2015 7:01 AM EDTBioLineRx (NASDAQ: BLRX) announced successful completion of the dose escalation stage of its ongoing Phase 2 study of BL-8040, and commencement of the expansion stage at the optimal dose of this novel treatment for acute myeloid leukemia (AML). Top-line results from the study are anticipated in the fourth quarter of 2015.
Results of the completed dose escalation stage, in which 22 patients participated, showed that all BL-8040 tested doses, up to 1.5 mg/kg, were found to be safe and well tolerated when administered in combination with Ara-C (Cytarabine). Building upon prior... More
